Tonix Pharma (TNXP) has released an update.
Research revealed that individuals with pre-existing chronic overlapping pain conditions (COPCs) are more likely to exhibit Long COVID symptoms. Analysis using TriNetX Analytics on health records from over 91 million U.S. individuals suggested that prior pain issues could worsen post-viral infection, COPCs might elevate Long COVID risks, and Long COVID could be considered as a new or aggravated COPC. The Company’s forward-looking statements regarding its products and market prospects reflect ambitions and predictions subject to uncertainties and potential discrepancies from future actual outcomes.
For further insights into TNXP stock, check out TipRanks’ Stock Analysis page.
For a comprehensive understanding of the announcement, you can read the full document here.
